Capricor Therapeutics (NASDAQ:CAPR) Rating Increased to Outperform at Oppenheimer

Key Points

• Oppenheimer upgraded Capricor Therapeutics to “outperform” from “market perform,” although the broader analyst consensus remains “hold” with a $29.15 price target.
• Capricor’s stock opened at $6.80 after an 8.1% increase, but the company reported a quarterly loss of $0.70 per share, missing estimates of $0.59.
• The FDA extended its review of deramiocel by three months to November 22, 2026, while investor concerns over clinical data and the HOPE-3 analysis have prompted securities-fraud lawsuits and added legal and regulatory uncertainty.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) was upgraded by stock analysts at Oppenheimer from a "market perform" rating to an "outperform" rating in a report issued on Tuesday, Marketbeat reports.

CAPR has been the subject of several other research reports. HC Wainwright reiterated a "neutral" rating on shares of Capricor Therapeutics in a report on Monday, July 27th. LADENBURG THALM/SH SH downgraded Capricor Therapeutics from a "buy" rating to a "neutral" rating in a report on Thursday, July 30th. Maxim Group lowered Capricor Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, July 30th. B. Riley Financial lowered Capricor Therapeutics from a "buy" rating to a "neutral" rating and set a $10.00 price target for the company. in a research note on Monday, July 27th. Finally, Wall Street Zen cut shares of Capricor Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 1st. Two analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Capricor Therapeutics currently has a consensus rating of "Hold" and a consensus price target of $29.15.

Capricor Therapeutics Trading Up 8.1%

Capricor Therapeutics stock opened at $6.80 on Tuesday. The firm has a 50-day moving average of $15.93 and a 200-day moving average of $24.72. The firm has a market cap of $395.35 million, a P/E ratio of -2.78 and a beta of 0.54. Capricor Therapeutics has a 1-year low of $2.96 and a 1-year high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.11). Research analysts forecast that Capricor Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 24,100 shares of the company's stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total transaction of $732,158.00. Following the transaction, the chief financial officer owned 11,223 shares in the company, valued at approximately $340,954.74. This represents a 68.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders sold 25,000 shares of company stock worth $759,158. 9.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Capricor Therapeutics

Several institutional investors have recently bought and sold shares of CAPR. KBC Group NV purchased a new stake in shares of Capricor Therapeutics during the first quarter valued at approximately $44,000. ACT Capital Management LLC bought a new stake in Capricor Therapeutics in the 4th quarter worth about $43,000. Allworth Financial LP boosted its holdings in shares of Capricor Therapeutics by 5,021.5% during the 4th quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company's stock valued at $96,000 after acquiring an additional 3,264 shares during the last quarter. State of Wyoming lifted its position in Capricor Therapeutics by 76.0% during the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company's stock valued at $128,000 after purchasing an additional 1,913 shares during the period. Finally, Royal Bank of Canada boosted its holdings in Capricor Therapeutics by 12.4% in the fourth quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company's stock worth $146,000 after purchasing an additional 557 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics News Roundup

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: The FDA extended deramiocel’s review by three months and set a new PDUFA target action date of November 22, 2026. Capricor said the extension allows the agency to review additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication. The continued review means the application remains active and gives the company more time to address regulatory questions. Capricor Therapeutics Announces Extension of PDUFA Target Action Date
• Neutral Sentiment: Multiple reports said the FDA’s decision followed new data submitted by Capricor. While the added analyses could improve the application, the three-month delay postpones a potential approval decision and leaves the commercial outlook uncertain. US FDA Extends Review of Capricor’s Muscle Disorder Therapy
• Negative Sentiment: Several law firms announced securities-fraud class actions or investor notices against Capricor and certain executives. The lawsuits allege that the company made material misstatements or omissions about deramiocel’s clinical data, the HOPE-3 statistical analysis plan, FDA compliance, and the path toward approval. The allegations have not been proven, but the litigation creates legal, financial, and reputational risks; investors have until September 28, 2026 to seek lead-plaintiff status. CAPR Investor Losses Securities Class Action Announcement
• Negative Sentiment: Investor concerns intensified after FDA briefing materials reportedly raised questions about changes to the HOPE-3 statistical analysis plan and the integrity of supporting data. Reports linked those concerns to a prior severe decline in CAPR shares, increasing uncertainty around approval probability and valuation. Levi and Korsinsky Capricor Investor Notice

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source